208 related articles for article (PubMed ID: 26134366)
21. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
23. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
[TBL] [Abstract][Full Text] [Related]
24. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
Hosonaga M; Arima Y; Sugihara E; Kohno N; Saya H
Cancer Sci; 2014 Jul; 105(7):779-87. PubMed ID: 24754246
[TBL] [Abstract][Full Text] [Related]
25. Sulforaphane inhibits growth of phenotypically different breast cancer cells.
Pawlik A; Wiczk A; Kaczyńska A; Antosiewicz J; Herman-Antosiewicz A
Eur J Nutr; 2013 Dec; 52(8):1949-58. PubMed ID: 23389114
[TBL] [Abstract][Full Text] [Related]
26. Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.
Yu T; Cho BJ; Choi EJ; Park JM; Kim DH; Kim IA
Oncotarget; 2016 Nov; 7(48):79089-79100. PubMed ID: 27738326
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
28. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
29. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
Brady SW; Zhang J; Tsai MH; Yu D
Cancer Biol Ther; 2015; 16(3):402-11. PubMed ID: 25692408
[TBL] [Abstract][Full Text] [Related]
30. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
31. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
[TBL] [Abstract][Full Text] [Related]
32. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ
Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941
[TBL] [Abstract][Full Text] [Related]
33. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
34. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Ma C; Niu X; Luo J; Shao Z; Shen K
Cancer Sci; 2010 Oct; 101(10):2220-6. PubMed ID: 20701607
[TBL] [Abstract][Full Text] [Related]
35. Sulforaphane, a cruciferous vegetable-derived isothiocyanate, inhibits protein synthesis in human prostate cancer cells.
Wiczk A; Hofman D; Konopa G; Herman-Antosiewicz A
Biochim Biophys Acta; 2012 Aug; 1823(8):1295-305. PubMed ID: 22640870
[TBL] [Abstract][Full Text] [Related]
36. Silencing the FOLR2 Gene Inhibits Cell Proliferation and Increases Apoptosis in the NCI-H1650 Non-Small Cell Lung Cancer Cell Line via Inhibition of AKT/Mammalian Target of Rapamycin (mTOR)/Ribosomal Protein S6 Kinase 1 (S6K1) Signaling.
Xu X; Jiang J; Yao L; Ji B
Med Sci Monit; 2018 Nov; 24():8064-8073. PubMed ID: 30415267
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
38. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
[TBL] [Abstract][Full Text] [Related]
39. AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib.
Buccinnà B; Ramondetti C; Piccinini M
Biochem Pharmacol; 2022 Oct; 204():115228. PubMed ID: 36007575
[TBL] [Abstract][Full Text] [Related]
40. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
